2-pyrrolidone has been researched along with Disease Models, Animal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bialer, M; Finnell, RH; Isoherranen, N; Merriweather, M; Roeder, M; Schurig, V; Spiegelstein, O; Triplett, AA; Yagen, B; Zhang, J | 1 |
| Chang, LY; Enghild, JJ; Fattman, CL; Oury, TD; Petersen, L; Termin, TA | 1 |
2 other study(ies) available for 2-pyrrolidone and Disease Models, Animal
| Article | Year |
|---|---|
Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity.
Topics: Animals; Butyrates; Disease Models, Animal; Female; Fetus; Levetiracetam; Mice; Piracetam; Pregnancy; Prenatal Exposure Delayed Effects; Pyrrolidines; Pyrrolidinones; Teratogens | 2003 |
Enhanced bleomycin-induced pulmonary damage in mice lacking extracellular superoxide dismutase.
Topics: Animals; Bleomycin; Bronchoalveolar Lavage Fluid; Collagen Type I; Disease Models, Animal; Extracellular Space; Hydroxyproline; Lung; Lung Diseases; Mice; Mice, Transgenic; Pulmonary Fibrosis; Pyrrolidinones; Superoxide Dismutase | 2003 |